Health Care & Life Sciences » Biotechnology | Asterias Biotherapeutics Inc.

Asterias Biotherapeutics Inc. | Ownership

Companies that own Asterias Biotherapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Broadwood Capital, Inc.
5,292,156
9.52%
0
0.79%
06/30/2018
The Vanguard Group, Inc.
1,206,876
2.17%
-37,293
0%
06/30/2018
British & American Investment Trust Plc (Invt Mgmt)
1,101,439
1.98%
300,481
5.52%
12/31/2017
Northeast Financial Consultants, Inc.
732,265
1.32%
0
0.33%
06/30/2018
Millennium Management LLC
490,775
0.88%
490,775
0%
06/30/2018
Thrivent Investment Management, Inc.
262,358
0.47%
0
0%
06/30/2018
BlackRock Fund Advisors
202,289
0.36%
-993,961
0%
06/30/2018
Thrivent Financial for Lutherans (Investment Portfolio)
191,316
0.35%
-31,539
0%
03/31/2018
Bridgeway Capital Management, Inc.
186,254
0.34%
34,400
0%
06/30/2018
Creative Planning, Inc.
180,313
0.33%
60,100
0%
06/30/2018

About Asterias Biotherapeutics

View Profile
Address
6300 Dumbarton Circle
Fremont California 94555
United States
Employees -
Website http://www.asteriasbiotherapeutics.com
Updated 09/14/2018
Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. The company is also focused on developing therapies to treat conditions with unmet medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.